InsiderTrades.com logo
Jim Cramer’s “The Biggest Drug Ever”
From Behind the Markets   |   Ad
This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.
Unlock the details of this groundbreaking opportunity here...

HEM Insider Trading

Insider Ownership Percentage: 12.15%
Insider Buying (Last 12 Months): C$4,060.00
Insider Selling (Last 12 Months): C$0.00

Hemostemix Insider Trading History Chart

This chart shows the insider buying and selling history at Hemostemix by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Hemostemix Share Price & Price History

Current Price: C$0.04
Price Change: ▼ Price Decrease of -0.005 (-11.11%)
As of 04/25/2024 06:18 PM ET

This chart shows the closing price history over time for HEM up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Jim Cramer’s “The Biggest Drug Ever”
From Behind the Markets   |   Ad
This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.
Unlock the details of this groundbreaking opportunity here...

Hemostemix Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/14/2023Thomas SmeenkDirectorBuy20,000C$0.07C$1,400.00
12/5/2023Thomas SmeenkDirectorBuy13,000C$0.07C$910.00
11/7/2023Thomas SmeenkDirectorBuy25,000C$0.07C$1,750.00
1/30/2023Thomas SmeenkDirectorBuy20,000C$0.22C$4,400.001,279,125
10/24/2022Thomas SmeenkDirectorBuy20,000C$0.15C$3,000.001,189,125
5/4/2022Thomas SmeenkDirectorBuy20,000C$0.30C$6,000.001,169,125
4/18/2022Thomas SmeenkDirectorSell300,000C$0.31C$93,210.001,149,125
See Full Table
Jim Cramer’s “The Biggest Drug Ever”
From Behind the Markets   |   Ad
This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.
Unlock the details of this groundbreaking opportunity here...

SEC Filings (Institutional Ownership Changes) for Hemostemix (CVE:HEM)

Hemostemix logo
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States. The company is also developing various types of cell products, such as synergetic cell populations, neural cell precursors, and cardiomyocyte cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.
Read More on Hemostemix

Today's Range

Now: C$0.04
Low: C$0.04
High: C$0.05

50 Day Range

MA: C$0.07
Low: C$0.05
High: C$0.10

52 Week Range

Now: C$0.04
Low: C$0.04
High: C$0.18

Volume

353,200 shs

Average Volume

45,690 shs

Market Capitalization

C$3.59 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.55

Who are the company insiders with the largest holdings of Hemostemix?

Hemostemix's top insider shareholders include:
  1. Thomas Smeenk (Director)
Learn More about top insider investors at Hemostemix.
Jim Cramer’s “The Biggest Drug Ever”
From Behind the Markets   |   Ad
This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.
Unlock the details of this groundbreaking opportunity here...